Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. - Test2 - elhamkhani - TriplyDB

Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.

Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.

http://www.wikidata.org/entity/Q37698613

about

Treating epidermal growth factor receptor-mutated non-small cell lung cancer-is dacomitinib the winner?Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy.Afatinib in advanced NSCLC: a profile of its use.The emerging treatment landscape of advanced non-small cell lung cancer.Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells

P2860

Q47108431-C47ED9DC-5F3F-4A14-AF6B-7D5E9871391B Q47261688-55CED0DF-582C-49FE-BEBA-D19537403D22 Q47695177-8891DFB1-4E63-4E3B-A76C-35D9ACA170AE Q52655265-76D97F96-DD20-43D5-89B4-A8658A8A4DD5 Q55342455-0316D057-8F72-42EF-A302-776D10F2131B Q58704602-74206EF8-112D-48E8-9795-981894FC6C45

P2860

Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.

http://www.wikidata.org/entity/Q37698613

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 30 January 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Treatment choice in epidermal ...... nce and clinical implications.

@en

Treatment choice in epidermal ...... nce and clinical implications.

@nl

type

label

Treatment choice in epidermal ...... nce and clinical implications.

@en

Treatment choice in epidermal ...... nce and clinical implications.

@nl

prefLabel

Treatment choice in epidermal ...... nce and clinical implications.

@en

Treatment choice in epidermal ...... nce and clinical implications.

@nl

P1433

Q37698613-23DBA371-625A-49E1-ACD4-DAD8C29C54CB

P1476

Q37698613-78B514E1-F9BA-48E7-9CB8-61C3BF6D33A3

P2093

Q37698613-4FC15D9F-1A96-4A81-8C47-C338C2B4E53A

Q37698613-BE8EC48D-685A-41FD-993A-521BC92C9DF1

P2860

Q37698613-01B721C6-5327-4267-A156-ADBA62C5497F

Q37698613-03E55D02-BA3F-40F8-9AE0-0A22DA73DF37

Q37698613-04AED694-DB22-4ACB-9E1C-882CF0624EB9

Q37698613-05320A54-A9A1-4E51-BFB1-6F3A6D493B41

Q37698613-08170FE7-5815-4EF6-A4F5-7532F1F89B50

Q37698613-09962EE6-F31B-4E4B-BE9E-DA6B22C75235

Q37698613-0AF53F94-CA9A-4B1F-8412-8C323AC2A9C0

Q37698613-0D485DA1-4FE3-4D25-AF4A-B3E77CF9C2C2

Q37698613-0F671B4A-BA5D-43D3-88DD-FC856F43BFD4

Q37698613-110F87DB-3A01-4E9B-A47C-9BB6EEBCBD01

P304

Q37698613-0DAE9EC9-723E-4DE7-AC29-FADD08AE90B1

P31

Q37698613-7BE64BA0-E99B-435F-B5FF-9A3CC1099A69

P356

Q37698613-5516EA43-8783-4799-A78F-34E31BC6C12B

P433

Q37698613-7D7B793D-709E-4841-A4C5-C45E9D75F3EC

P478

Q37698613-775D56CC-56F9-4C85-A9C7-5A8725274AB3

P50

Q37698613-41A25CB3-71DA-4D3B-B466-D0A633F781D4

Q37698613-A2B4426B-82CB-4B63-86AE-86AA8F3C3327

P577

Q37698613-FA21B789-A537-43D3-ACA9-4772CAF6A41E

P698

Q37698613-CCFBF2DA-4DE0-41E0-97B6-F7A58281DCAB

P932

Q37698613-72B1E474-68F1-4C01-8064-35D7376AA522

P356

1758834016687262

P1433

Therapeutic advances in medical oncology

P1476

Treatment choice in epidermal ...... ence and clinical implications

@en

P2093

Oscar Juan

http://www.w3.org/2001/XMLSchema#string

Sanjay Popat

http://www.w3.org/2001/XMLSchema#string

P2860

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.

P304

201-216

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1758834016687262

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28344665

http://www.w3.org/2001/XMLSchema#string

P932

5349427

http://www.w3.org/2001/XMLSchema#string